A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancerResearch in context
Summary: Background: To investigate the efficacy and safety of first-line treatment with tislelizumab plus low-dose bevacizumab and standard chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. Methods: This open-label, multicenter, single-arm, phase 2 study (NCT05247...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537025002408 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|